Evidence map›Paper›PMID 33090726›Full record

ArticleJournal of evidence-based medicine2020

An instrument for evaluating the clinical applicability of guidelines.

Zeng Linan, Yi Qiusha, Zhang Chuan, Huang Chao, Li Hailong, Yang Chunsong, Lin Mao, Huang Liang, Liu Dan, Kang Deying and 8 more

Abstract read
In one paragraph

Article in Journal of evidence-based medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zeng LinanDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Yi QiushaDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.ORCID https://orcid.org/0000-0001-8096-0228
Zhang ChuanDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Huang ChaoMedical Management Service Guidance Center, National Health Commission of the People's Republic of China, Beijing, P.R. China.
Li HailongDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Yang ChunsongDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Lin MaoDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Huang LiangDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Liu DanDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
Kang DeyingChinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, P.R. China.ORCID https://orcid.org/0000-0003-1488-7047
Liu GuanjianChinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, P.R. China.
Liu QiaolanWest China School of Public Health, Sichuan University, Chengdu, P.R. China.
Zhao RongshengDepartment of Pharmacy, Peking University Third Hospital, Beijing, P.R. China.
Zhang JunhuaCentre for Evidence-Based Medicine, Tianjin University of TCM, Tianjin, P.R. China.
Li YoupingChinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, P.R. China.
Liu HanminKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, P.R. China.
Wang QiangMedical Management Service Guidance Center, National Health Commission of the People's Republic of China, Beijing, P.R. China.
Zhang LingliDepartment of Pharmacy/Evidence-Based Pharmacy Centre, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.

Funding

National Health Commission of the People's Republic of China
6 · The paper itself

Abstract

objectiveTo establish an instrument for evaluating the clinical applicability of guidelines from the guideline-users' perspective.

methodsWe established this instrument through forming a working group, forming an initial list of items based on a qualitative systematic review, establishing initial instrument via two rounds of modified Delphi surveys, and external review the initial instrument.

resultsThe results of modified Delphi surveys establishing appraisal aspects, appraisal items, general information of the evaluator met the preset requirements. The instrument includes three parts: general information of the evaluator (12 items), evaluation of clinical applicability (12 items, including items on the availability, readability, acceptability, feasibility, and overall applicability of guideline), and scoring scheme.

conclusionsThe instrument for evaluating the clinical applicability of guidelines from the guideline-users' perspective provides criteria and methods for improving the clinical applicability of guidelines during development and updating.

Indexed as

clinical applicabilityclinical practice guidelineevaluation instrument

Identifiers

PMID33090726
PMCPMC7984040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.